Data XNUMX September Kun Kun, Kang Le Wei Shi announced that the independent data monitoring committee for the phase III protective efficacy clinical trial of the self-developed recombinant trivalent human papillomavirus (16/18/58) vaccine (Escherichia coli) has completed the interim analysis unblinding, main efficacy endpoints and safety assessment, with results meeting expectations.
Lihat Asli
Halaman ini mungkin berisi konten pihak ketiga, yang disediakan untuk tujuan informasi saja (bukan pernyataan/jaminan) dan tidak boleh dianggap sebagai dukungan terhadap pandangannya oleh Gate, atau sebagai nasihat keuangan atau profesional. Lihat Penafian untuk detailnya.
Kang Le Wei Shi mengumumkan pengungkapan buta klinis Fase III vaksin HPV tiga nilainya, analisis tengah periode sesuai harapan
Data XNUMX September Kun Kun, Kang Le Wei Shi announced that the independent data monitoring committee for the phase III protective efficacy clinical trial of the self-developed recombinant trivalent human papillomavirus (16/18/58) vaccine (Escherichia coli) has completed the interim analysis unblinding, main efficacy endpoints and safety assessment, with results meeting expectations.